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IGT             -  Impaired glucose tolerance 
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OSAS             -         Obstructive Sleep apnea Syndrome 
SNS                -          Sympathetic nervous system  
BMI                -         Body mass index 
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INTRODUCTION 
 
Sleep is a complex neuro chemical process essential in humans for the maintenance of 
health. Sleep can be defined as a period of rest for the body and mind during which 
consciousness is in partial or complete abeyance and the bodily functions are partially 
suspended. Sleep restores bodily functions and it has a great role in cerebral changes to 
facilitate memory consolidation and cognitive functions. Sleep has a close relation with 
cardiovascular, immune and hormonal diurnal cycles.
1
 
 
Excessive Daytime Sleepiness [EDS] is defined in International Classification of 
Sleep Disorders based on the behaviour of falling asleep, including difficulty maintaining 
alertness or wakefulness and unintentionally falling asleep.
2
 Excessive daytime sleepiness is 
one of the most common sleep-related patient symptoms affecting about 20 percent of the 
world population. Persons with excessive daytime sleepiness are at risk of road traffic 
accidents and have poorer health than comparable adults. The most common causes of 
excessive daytime sleepiness are sleep deprivation, diabetic mellitus, obesity, obstructive 
sleep apnea and sedating medications. Other potential causes of excessive daytime sleepiness 
consist of certain medical and psychiatric conditions and sleep disorders, such as narcolepsy.
3 
Diabetes is a condition of endemic proportions with increasing prevalence. By 2030, 
it is expected to have an effect on almost 439 million people ie about 7.7% of total world 
population. Among Diabetes mellitus, Type 2 diabetes mellitus (T2DM) accounts for most 
cases of diabetes,ie about 85–95%. Among the factors considered responsible for this sharp 
increase in prevalence are increased geriatric population, unhealthy diet, overweight, obesity, 
and a sedentary lifestyle
4
. There is evidence that sleep impairment should also be considered 
a T2DM risk factor because, in addition to some of the leading risk factors listed above, it 
seems to be independently associated with diabetes. Both the development and control of 
T2DM seem to be affected by sleep quality and duration
5
. Many researchers suggest that 
optimizing sleep duration and quality might improve the metabolic control of individuals 
with T2DM and Type 1 diabetes mellitus (T1DM). On the other hand, it should also be taken 
into account that, poor glycemic control in T2DM and T1DM individuals may favour the 
development of sleep disorders.
5-8
 In addition to diabetes, overweight and obesity have been 
growing in prevalence at an alarming rate.
9 
Sleep loss is also increasing sharply. Chaput et 
al.
10
 reported that in 1960 the modal adult sleep duration was between 8.0 and 8.9 hrs, 
whereas in 2004 the number of sleeping hours of more than 30% of adults aged 30–60 years 
had dropped to less than 6 hours. This clearly shows that the interacting epidemics of 
diabetes, obesity and sleep impairment form a vicious circle.
11,12 
The increased prevalence of metabolic disorders in our society is aggravated by 
endemic voluntary postponement of bed time and by the current sedentary lifestyle, leading 
to epidemic proportions of obese people. Sleep disorders are commonly found in patients 
with type 2 diabetes.
13
 Diabetes and chronic loss of sleep show the fact that, both affect 
millions and one depends on the other. Associated with the endemic condition of diabetes in 
our society, chronic sleep loss is increasingly common in industrialized societies and affects 
about 45% of all adults.
14
 Sleep is a complex behavioural state that occupies one third of the 
human life span. Therefore proper sleep pattern is very much necessary to improve quality of 
life in diabetic and obese patients. However, there is increasing evidence that sleep also 
modulates the metabolic, endocrine and cardiovascular systems.
15
 Sleep disturbances are 
common and can be detrimental to the health, mood, and quality of life of the people with 
diabetes.
  
A study revealed a marked reduction in glucose tolerance and insulin sensitivity after 
8 nights of 5-hour bedtimes compared with 8-hour bedtimes.
16
 Various mechanisms have 
been explored and suggested that there is a potential link between poor sleep patterns and 
negative health outcomes like impaired glucose regulation and subsequent increased risk of 
Type 2 DM.
5
 Evidence from cross-sectional studies suggests that a diabetic condition may 
involve a reduction in sleep duration or an impairment of sleep quality.
17 
Excessive day time sleepiness [EDS] is characterized by persistent sleepiness and 
often a general lack of energy, even after having apparently adequate night time sleep. 
Sudden involuntary sleep onset and micro sleeps are common complications. Diabetes and 
obesity are the two main factors contributing to EDS.
18 
Sleep and type II diabetes 
In the past, T2DM was considered a disease of older age groups. Today, it is well 
established that even with a higher incidence in older people, T2DM may occur at any age. 
This change is attributed to the spread of a ‘Western modern society lifestyle’, which 
includes higher food consumption, sedentary behaviour, and shorter sleep duration.
19 
Sleep deprivation has been shown to be a risk factor for impaired glucose tolerance 
(IGT), 
17 
weight gain, insulin resistance, and T2DM itself. 
20-22
 At the same time, evidence 
from some epidemiological studies indicates that not only short          (6 hrs or less), but also 
long sleep duration (9 hrs or more) is associated with increased prevalence of IGT and T2DM 
10,23 
and with high fasting plasma glucose and high HbA1c levels.
24
 A study conducted with 
1139 men found that subjects reporting short sleep duration (5–6 hrs of sleep per night) were 
twice as likely to develop diabetes than those who slept between 6 hrs and 8 hrs, and those 
reporting long sleep duration (8 hrs) were more than three times as likely to develop diabetes 
over a period of 15 years.
25
 The reason why more sleep negatively impacts metabolism has 
recently become the subject of much speculation.
 
Evidence for a modulatory impact of sleep on many physiological functions, 
including metabolic regulation and endocrine release, has been reported more than four 
decades ago. Night time hormonal release and glucose control are dependent on the 
occurrence of specific sleep stages. 
26-28
Human sleep is composed of rapid-eye-movement 
(REM) sleep and stages 1, 2 and 3 of non-REM (NREM) sleep. During the deeper stage of 
non-REM sleep, i.e. slow wave sleep (SWS) or stage NREM 3, brain glucose utilization and 
sympathetic nervous activity are decreased and parasympathetic nervous activity is increased, 
relative to both wake and REM sleep. SWS are also associated with robust elevations of 
growth hormone (GH) levels, while pituitary–adrenal activity is inhibited.28 Hence SWS is 
likely to play a major role in total body glucose regulation. More recently, orexin neurons in 
the lateral hypothalamus have been identified as playing a central role in the maintenance of 
arousal as well as feeding behaviour, 
29,30
 suggesting an impact of sleep duration on appetite 
regulation. 
Another cause of the daytime sleepiness in patients with diabetes is the increased 
levels of inflammatory cytokines.
31
 Presently, these cytokines are accepted as mediators of 
sleepiness, and they are closely involved in the pathogenesis of Type 2 diabetes.
32 
Sleep and Obesity
 
Sleepiness is the inability to maintain alertness and manifests characteristic 
hypersomnic behaviours and decreased functional outcomes. Daytime sleepiness is a 
common outcome of sleep disturbances. Obesity is also biochemically associated with 
sleepiness. That is, adipose tissue produces somnolence inducing inflammatory cytokines 
such as tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6.
31 
The cause of symptomatic daytime sleepiness in the obese population clearly needs 
further evaluation. There are many features of obesity that drive various aspects of obesity 
generated disease and disability. Daytime sleepiness may be related to the extent of adiposity, 
the distribution of adiposity, or metabolic, inflammatory, physical, mental, or psychological 
disturbances experienced by obese subjects.
33 
The symptoms of daytime sleepiness is measured using a validated instrument, the 
Epworth Sleepiness Scale (ESS).and the sleep quality of the past month is measured by 
Pittsburgh Sleep Quality index[PSQI]. It is hypothesized that the extent of symptomatic 
daytime sleepiness, measured with the ESS would correlate with one or several of these 
broad areas and that disturbance in these areas would explain substantial variance of the ESS 
scores.
33 
The ESS represents a validated questionnaire containing eight items that measure a 
subject's expectation of dozing in eight hypothetical situations. A score greater then 10 is 
considered indicative of excessive daytime sleepiness and a PSQI score of six or more were 
considered poor sleepers.
34,35
 
Other Factors Contributing To EDS
18
 
 Insufficient quality or quantity of night time sleep. 
 Misalignments of the body's circadian pacemaker with the environment  
 An underlying sleep disorder, such as narcolepsy, sleep apnea, hypersomnia or 
restless legs syndrome. 
 Disorders such as clinical depression or atypical depression and obesity 
 Tumours, head trauma, anaemia, kidney failure, hypothyroidism or an injury to the 
central nervous system. 
 Drug abuse. 
 Genetic predisposition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
 Abdulbari Bener et al., in their study findings observed that disturbed sleep was 
more prevalent in the diabetic population. Also, excessive daytime sleepiness was observed 
more in diabetic patients, especially in women. Sleep loss varied significantly by gender in 
diabetic patients. A significant difference was observed in ESS scores between both genders. 
Obesity was more common among diabetic women with poor sleep than men, while physical 
activity was significantly less in women compared to men.
36
 
 
Adriana et al., in their study in Romanian obese Type 2 Diabetic patients revealed 
that EDS is highly prevalent in Romanian Patients with Type 2 Diabetes and should be 
systematically screened for, especially among obese individuals with higher waist 
circumference and poor diabetes control.
37
 
 
O. Resta et al., in their study clearly shows that severe obesity, even in the absence of 
OSAS, is associated with sleep-related disorders and EDS. All these alterations may be partly 
responsible for a lower quality of life, a higher prevalence of medical complications, an 
increased risk of occupational injury, and both social and family problems characterizing 
obese patients, independently of the presence of OSAS. Persons with excessive daytime 
sleepiness are at risk of motor vehicle and work-related incidents, and have poorer health 
than comparable adults. The evaluation and management of excessive daytime sleepiness is 
based on the identification and treatment of underlying conditions (particularly obstructive 
sleep apnea), and the appropriate use of activating medications.
38 
Kevin Ruggles et al., in their study suggest that, EDS is a common condition which 
results in a significant public health problem. Patients suffering from EDS are at increased 
risk for automobile accidents and work related injury. There is also evidence that sleep 
disorder are generally under diagnosed and under treated.
39 
 
John B. Dixon et al., in their study showed the presence of excessive daytime 
sleepiness, as measured by the ESS, was common in obese subjects but was not related to the 
presence or severity of OSA or other polysomnography findings in a selected group. It was 
related to older age, male gender, smoking, type 2 diabetes, symptoms of depression, and 
poor quality of life. It was also strongly associated with symptoms of disturbed nocturnal 
sleep.
33
 
 
E. O. Bixler et al., in their study indicated that when diagnosing a case with a 
complaint of EDS, sleep disturbance (e.g. due to sleep apnea) should not be considered the 
only cause. It appears that EDS is more strongly associated with mood factors (e.g. 
depression) as well as metabolic factors (obesity and/or diabetes), i.e. the metabolic 
syndrome. EDS appears to be more prevalent in the very young, suggesting unmet sleep 
needs and/or depression. EDS is also more prevalent in the very old, most likely associated 
with increasing medical illnesses and health issues. Their findings indicated that patients with 
a complaint of EDS should be adequately assessed for depression, obesity, and/or diabetes 
both in the presence or absence of sleep apnea and then treated appropriately.
40
 
 
Anna-Kaisa Renko et al., in their study found out the relation of snoring, sleep apnea 
and daytime sleepiness as independent indices of obesity related to Type II diabetes    
(T2DM).Their study supports the earlier findings showing that sleep apnea is fairly common 
among subjects aged 61–63 years, and that male gender and BMI are independently 
associated with sleep apnea. Diabetic subjects suffer more often from habitual snoring than 
normoglycemic ones, and it seems that T2D, but not IGR, is independently associated with 
snoring. Daytime sleepiness seemed to be linked with depression but not with using the sleep 
medication, IGR and T2D. Their study also supports the previous findings showing that sleep 
apnea, habitual snoring and daytime sleepiness are connected with anthropometric 
measures.
41 
 
 
Eileen R. Chasens et al., in their study explored the association between daytime 
sleepiness on physical activity and functional outcomes in veterans with T2DM. It is 
suggested that daytime sleepiness is highly prevalent in male veterans with T2DM and that it 
is associated with decreased physical activity and poor functional outcome. They concluded 
that daytime sleepiness may impede physical activity among veterans with diabetes, 
confounding self-management.
42
 
 
Tze Pin Ng et al., in their study affirmed the high prevalence of EDS in an Asian 
multi-ethnic population. Daytime sleepiness is associated with a wide multiplicity of risk 
factors in the community, including sleep behaviour, breathing, work and medically related 
factors, representing identifiable risk groups in the general population for targeted 
intervention. Many of these risk factors are highly prevalent in the population, and contribute 
substantially to the public health significance of EDS in the community.
43 
 
Mark.T.U.Barone et al., in their study suggested that sleep debt, OSA, obesity and 
T2DM are part of a vicious circle, where one influences, provokes, or impairs the others. 
Sleep exerts marked modulatory effects on glucose metabolism by influencing the balance 
and levels of hormones, including leptin, ghrelin, insulin and cortisol, in addition to the 
activity of the SNS. Sleep loss and sleep disorders, e.g., OSA, can be understood as stressors, 
triggering SNS activation, secretion of stress hormones, and inflammatory responses. These 
physiological defense mechanisms alter glucose tolerance and sensitivity to insulin and 
leptin, impairing appetite regulation. Therefore, when chronically activated, these stress 
responses favour the development of obesity and T2DM. In addition, shorter sleepers have 
more opportunity for food consumption and tend to be more fatigued and less active during 
the day, which favour obesity. On the other hand, obesity itself, especially when central, 
leads to OSA, to inflammatory processes, and to the development of T2DM. Thus, they 
concluded that it is difficult to isolate a cause and an effect from this neuro-endocrine-
metabolic misbalance, since sleep characteristics (disorders or duration) may impact 
neurological and endocrine systems to promote obesity and T2DM, while obesity and T2DM 
may impact sleep as well. Therefore, while obesity and T2DM are favoured and aggravated 
by short sleep duration or sleep disorders, sleep may be impaired by these two widespread 
metabolic conditions.
44
 
Dev Banerjee et al., in their study recognised that Excessive Day time Sleepiness 
(EDS) has detrimental consequences such as road traffic accidents, impaired psychological 
functioning and reduced work performance. EDS can result from multiple causes such as 
sleep deprivation, sleep fragmentation, neurological, psychiatric and circadian rhythm 
disorders. Treating the underlying cause of EDS remains the mainstay of therapy but in those 
who continue to be excessively sleepy, further treatment may be warranted. Recently, the 
advent of modafinil has broadened the range of therapeutic options. Modafinil has a safer 
side effect profile. Traditionally the amphetamine derivatives, methylphenidate and pemoline 
psychostimulants were the commonest form of therapy for EDS particularly in conditions 
such as narcolepsy.
 4
 
OVERVIEW 
 
DEFINITION 
Excessive Daytime Sleepiness [EDS] is defined in International Classification of 
Sleep Disorders based on the behaviour of falling asleep, including difficulty maintaining 
alertness or wakefulness and unintentionally falling asleep.
2 
 
AETIOLOGY 
Excessive daytime sleepiness occur due to hypersomnias 
 Primary hypersomnia of central origin  
 Secondary hypersomnia.   
Narcolepsy is the most common of primary hypersomnia reported. Less common are the 
primary hypersomnia of Idiopathic origin  and other rare primary hypersomnias  like Kleine-
Levin syndrome and menstrual hypersomnia. 
Secondary hypersomnias are caused due to Sleep disorders. Sleep related breathing 
disorders include excessive daytime sleepiness secondary to obstructive sleep apnea. 
Behavioural sleep deprivation is common in adolescents and shift workers. Other sleep 
disorders include circadian rhythm sleep disorders, sleep-related movement disorders. 
Medical or psychiatric conditions also lead to secondary hypersomnias. Medication effects 
include prescription, non prescription, and drugs of abuse. Psychiatric conditions include 
depression. Medical conditions like head trauma, stroke, cancer, inflammatory conditions like 
encephalitis, neurodegenerative conditions can also lead to secondary hypersomnias. 
Excessive sleepiness caused by a primary hypersomnia of central origin (e.g., narcolepsy, 
idiopathic hypersomnia) is less common.
46
 
 
SLEEP DEPRIVATION 
Sleep deprivation is probably the most common cause of excessive daytime 
sleepiness. Symptoms can occur in healthy persons even after mild sleep restriction. Most 
types of chronic insomnia including primary insomnia, psychopathological insomnia, and 
paradoxical insomnia are associated with daytime hyper arousal rather than excessive 
daytime Sleepiness. The presence of excessive daytime sleepiness in a patient with insomnia 
suggests co- morbidity such as a sleep-related breathing disorder or a mood disorder.
47 
 
MEDICATION CLASSES COMMONLY ASSOCIATED WITH DAYTIME 
SLEEPINESS 
48
 
 
Alpha-adrenergic blocking agents 
Anticonvulsants (e.g., hydantoins,succinimides) 
Antidepressants (monoamine oxidase inhibitors, tricyclics, selective serotonin reuptake 
inhibitors) 
Antidiarrhoea agents 
Antiemetics 
Antihistamines 
Antimuscarinics and antispasmodics 
Antiparkinsonian agents 
Antipsychotics 
Antitussives 
Barbiturates 
Benzodiazepines, other γ-aminobutyric acid affecting agents, and other anxiolytics 
Beta-adrenergic blocking agents 
Genitourinary smooth muscle relaxants 
Opiate agonists and partial opiate agonists 
Skeletal muscle relaxants 
 
PATHOPHYSIOLOGY 
Although the pathophysiological pathways linking sleep to diabetes are still under 
study. It is not as simple as a linear cascade, but rather it is a complex and multifactorial 
neuro-endocrine-metabolic network. This complex, interactive system is divided into its best-
known components below.
11,49
 
 
 1. Sympathetic contribution 
Activation of the sympathetic nervous system (SNS) is one of the best understood 
consequences of stressful situations, such as OSA and other sleep impairment, including 
sleep curtailment.
20,50,51
 Among the pathways through which SNS activation is likely to 
predispose to obesity, glucose impairment, metabolic syndrome and T2DM 
52,53
, the two most 
well known are the inhibition of leptin secretion
54
 and the stimulation of the hypothalamic–
pituitary–adrenal axis (HPA), resulting in excessive cortisol secretion, which impairs glucose 
homeostasis.
51,55
 
 2. HPA axis contribution 
SNS, activated by sleep impairment, stimulates the HPA axis. Cortisol, a 
glucocorticoid secreted as a result of HPA activity, has effects throughout the body, some of 
them tightly correlated to metabolism in peripheral tissues. Exposure to excessive 
glucocorticoid levels leads to insulin resistance, weight gain and metabolic syndrome, by 
increasing glucose output and lipogenesis, decreasing glucose utilization and inhibiting lipid 
mobilization in the presence of insulin, especially from the visceral adipose tissue.
23,55-57 
  Sleep disorders affect both the SNS and the HPA axis, negatively impacting carbohydrate 
metabolism, favouring the development of glucose intolerance, which might lead to T2DM. 
On the other hand, it is interesting to note that HPA hyperactivity is a known cause of sleep 
impairments such as insomnia, sleep fragmentation, shortened sleep time.
23, 55, 58 
 3. Appetite regulation contribution 
Sleep disorders impact the regulation of appetite, leading to decreased satiety and 
increased caloric intake, which strongly contribute to the development of obesity. Obesity is 
one of the main components of the metabolic syndrome and is a step toward T2DM and 
OSA.
12
 There are several hormones and neuropeptides involved in appetite regulation such as 
cholecystokinin, glucagon-like peptide-1,and peptide YY3-36, among others, but the more 
important hormones that affect sleep impairment are leptin, insulin and ghrelin. Leptin is 
primarily produced by adipocytes, and its level in the blood is proportional to fat mass. 
Insulin is secreted by pancreatic beta-cells acutely in response to food intake. Those 
hormones convey anorexigenic information to the hypothalamus, suppressing appetite and 
affecting energy expenditure. The administration of exogenous leptin fails to reduce adiposity 
in most cases of human obesity. The reason for this is a state of leptin resistance, which 
explains the high circulating leptin levels observed.
 59
 The possible mechanisms of leptin 
resistance include the limitation of its transport into the brain, inhibition of leptin signaling 
pathways in leptin-responsive hypothalamic neurons, high serum levels of leptin-interacting 
proteins, or genetic mutation in its receptor.
59,60,61
 As expected because of leptin resistance in 
overweight, its serum level has been shown to correlate positively with BMI, insulin, 
insulin/glucose ratio, AHI, and oxygen desaturation time. 
62 
 
In contrast with the hunger- and appetite-suppressing signals of leptin and insulin, 
ghrelin conveys an appétite stimulating message to the hypothalamus.
63
 Ghrelin is primarily 
secreted by the stomach and rapidly suppressed by food intakes. 
59,64 
Studies have found that 
short sleep duration is associated with decreased levels of leptin and increased levels of 
ghrelin. 
11,65 
 
Therefore, impairment of appetite regulation might be a consequence of short sleep 
duration or due to leptin and insulin resistance (the hallmarks of obesity and T2DM) and be 
exacerbated by OSA. To explore the association between the sleep–wake cycle, appetite and 
metabolism, it is necessary to consider the role of the neuropeptides called orexins, 
orhypocretins. Orexin A and orexin B are excitatory neuropeptides found in the lateral 
hypothalamus and perifornical area. They are both stimulated by ghrelin, promote 
wakefulness, and increase appetite and SNS activity. Moreover, besides the down regulation 
of satiety, the promotion of short sleep time, and the stimulation of the HPA axis by increased 
SNS activation, ghrelin promotes adipogenesis and decreases energy expenditure, fat 
catabolism and lipolysis. Therefore, this might be one of the main reasons why individuals 
with short sleep duration are prone to gain weight and increase the risk of developing OSA 
and T2DM.
63,64
 
 3. Contributions of inflammatory processes 
Obesity and T2DM are known to be associated with chronic systemic inflammation
66
. 
C - reactive protein was identified as one of the major serum leptin interacting proteins, and it 
seems to be one of the main agents responsible for leptin resistance.
61
 Human CRP directly 
inhibits the binding of leptin to its receptors and blocks its ability to signal in cultured cells. 
In addition to sleep restriction, Cytokines may either promote or inhibit sleep through their 
interactions with different brain regions. Some of the sleep alterations that cytokines may 
induce could be mediated by changes in nitric oxide synthesis, effects on neuro hormonal 
systems such as growth hormone releasing hormone, and activation of the HPA axis. 
Therefore, since obesity, T2DM, sleep disorders and sleep restriction are associated with 
increased inflammatory response, it is concluded that the pro-inflammatory effects of one 
disorder influence the expression of the other disorder.
67
 
 
Pathway composing the vicious circle of T2DM and Sleep  
 
 
 
 
 
 
 
 
TREATMENT 
 
Addressing the underlying cause is the mainstay of treatment of excessive daytime 
sleepiness. Modafinil (Provigil) is considered to be the first-line activating agent for the 
treatment of excessive daytime sleepiness. It is indicated for the treatment of persistent 
sleepiness associated with OSA in patients already being treated with CPAP, and for the 
treatment of daytime sleepiness in patients with shift work disorder. Modafinil is 
pharmacologically distinct from and has a much lower potential for abuse (Schedule IV) than 
the amphetamines, and has a generally benign side effect profile. Other medications that must 
be used with caution to induce alertness in somnolent patients include the amphetamines 
(dextroamphetamine [Dexedrine], methylphenidate [Ritalin]) and pemoline.
68-70
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Prevalence and Assessment of Excessive Daytime Sleepiness in Diabetic and Obese Patients  
 
18 
METHODOLOGY 
 
Objective: 
To study the prevalence  of Excessive Day time Sleepiness [ EDS] in diabetes and obese 
patients by assessing the quality and quantity  of sleep by Epworth[ ESS] and Pittsburgh  Sleep 
Quality Index [PSQI] Scale and also to provide patient education to improve quality and quantity 
of  sleep. 
 
Study Design: 
It is a prospective observational study. 
 
Study Site: 
The study was conducted in the department of Diabetology, Kovai Medical Center and 
Hospital, a multispecialty hospital in Coimbatore, Tamilnadu. 
 
Study Period: 
The study was conducted over a period of five months from September2011 to January 
2012. 
 
Study Population: 
Both male and female patients diagnosed with Type II Diabetes Mellitus & Obesity within the 
age group of 20-65 were included in the study. 
Methodology 
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19 
Sources of Data: 
The data was collected through direct patient interview and also from various sources 
such as patient’s case sheet, treatment chart and laboratory reports. 
Study Procedure: 
In this prospective observational study, both male and female patients who are diagnosed 
with Type II Diabetes mellitus, overweight and obese patients within the age group of 20-65 are 
included. The patients who do not wish to complete the questionnaire and those diagnosed with 
obstructive sleep apnea are excluded. Hospital Ethical Committee approval was obtained. All the 
patients are taken directly from the doctor’s consultation room. The laboratory values and 
medications are noted from the patient’s chart.  
Data are collected and assessed by providing two questionnaires namely Epworth 
Sleepiness Scale [ESS] and Pittsburgh Sleep Quality Index [PSQI]. The former assess the 
daytime somnolence in patients and the latter assess the sleep quality during the past month. 
 
The Epworth sleepiness scale is a brief, valid, reliable measure used to assess the 
likelihood that an individual will fall asleep in a series of situations such as watching TV, sitting 
and reading, sitting inactive in a public place like a theatre or meeting, travel in a car as a 
passenger for an hour without break, lying down to rest in the afternoon when circumstances 
permit, sitting and talking to someone, sitting quietly after lunch without alcohol and travel in a 
car while stopped for a few minutes in the traffic. The scoring of the answers is 0-3, with 0 being 
“would never doze”, 1 for “slight chance of dozing”, 2 for “moderate chance of dozing” and 3 
for high chance of dozing”. A score lower than 10 distinguishes as getting enough sleep, 10-12  
comes in the borderline and greater than 12 as very sleepy and they should seek medical advice. 
Methodology 
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 Pittsburgh sleep quality index (PSQI) was used to check the sleep habits of diabetic 
patient during the past month. The situations in the questionnaire  were classified as during the 
past month how often had they taken medicine to help them sleep, wake up in the middle of the 
night or early morning, cannot get to sleep within 30 minutes, have to get up to use the 
bathroom, had bad dreams, have pain. For each of the questions of the questionnaire, response 
was classified as “never”, “once a week” and “more than once a week”. Individuals with a score 
of six or more were considered poor sleepers. Patient counselling to improve the quality and 
quantity of sleep were also given. 
 
Data Analysis 
Chi-square test will be applied to find out statistical significance of BMI, Physical 
activity, Age group factors on prevalence of excessive day time sleepiness in diabetic and obese  
patients.. Values of P <0.05 were considered statistically significant.  
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Table: 1 GENDER WISE DISTRIBUTION OF STUDY POPULATION 
S.No Gender N=160 Percentage 
1 Male 88 55 
2 Female 72 45 
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Table: 2 AGE WISE DISTRIBUTION OF STUDY POPULATION 
S.No Age Group N=160 Percentage 
1 25-35 8 5 
2 36-45 36 22.5 
3 46-55 54 33.7 
4 56-65 62 38.7 
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Table: 3 EDUCATIONAL QUALIFICATION AMONG STUDY POPULATION 
(N=160) 
S.No Educational Qualification Male(%) Female(%) 
1 illiterate 12.5 33.3 
2 1-10 25 20.5 
3 10-12 37.5 23.1 
4 ≥Degree 25 23.1 
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 Table: 4 MONTHLY INCOME AMONG STUDY POPULATION (N=160) 
S.No Monthly income Percentage of Patients 
1 <5000 46.8 
 
2 5000-15,000 36.7 
3 >15,000 16.5 
 
 
 
 
 
 
Prevalence and Assessment of Excessive Daytime Sleepiness in Diabetic and Obese Patients  
 
25 
Table: 5 GENDER WISE PREVALENCE OF EDS 
Sl No. Gender With EDS Without EDS 
1 Male 40 48 
2 Female 39 33 
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Table: 6 GENDER WISE DISTRIBUTION OF PREVALENCE OF EDS AMONG 
STUDY POPULATION  
 
S.No Gender  No. of patients Percentage of  Patients 
1 Male 88 45.4 
2 Female 72 54.2 
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Table: 7 AGE WISE DISTRIBUTION OF PREVALENCE OF EDS 
 
 
 
 
 
S.No Age 
Group 
Number of  
Patients 
Percentage of 
patients 
P value 
1 25-35 4 5.1  
 
0.300 
2 36-45 14 17.7 
3 46-55 25 31.6 
4 56-65 36 45.6 
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Table: 8 PREVALENCE OF EDS IN REGARD TO BMI OF THE 
SUBJECTS (N=79) 
 
 
 
 
 
 
S.No BMI With EDS(%) Without EDS(%) P value 
1 18-24.9 31.2 68.8 
0.000 2 25-29.9 62.3 37.7 
3 ≥ 30 84.2 15.8 
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Table: 9 BMI OF BOTH MALE AND FEMALE PATIENTS WITH EDS 
S.No BMI Male(%) Female(%) 
1 Normal(18- 24.9) 37.5 25.6 
2 Overweight(25-29.9) 40 56.4 
3 Obese(≥30) 22.5 17.9 
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Table: 10  PREVALENCE OF EDS IN REGARD TO PHYSICAL ACTIVITY OF 
SUBJECTS 
S.No Physical Activity With EDS(%) Without EDS(%) P Value 
1 Moderate 26 74  
0.000 2 Sedentary 59.5 40.5 
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Table: 11 PHYSICAL ACTIVITY OF PATIENTS WITH EDS 
S.No Physical Activity Male(%) Female(%) 
1 Sedentary 77.5 89.7 
2 Moderate 22.5 10.3 
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Table: 12 PREVALENCE OF EDS IN REGARD TO DURATION OF DIABETIC 
YEARS IN THE STUDY POPULATION 
 
 
 
 
 
 
 
 
 
S.No Duration of Diabetic years With EDS Without EDS 
1 0-5 46 49 
2 6-10 15 22 
3 11-15 13 6 
4 16-20 3 3 
5 21-25 2 1 
Prevalence and Assessment of Excessive Daytime Sleepiness in Diabetic and Obese Patients  
 
33 
Table: 13 PERCENTAGE PREVALENCE OF EDS IN THE SUBJECTS WITH 
REGARD TO SOCIAL HABITS 
 
S.No Social Habits With EDS(%) Without EDS 
1 Smoker 22.2  15.2 
2 Alcoholic 11.1  7.6 
3 Tea/Coffee 98.7 95 
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Table: 14 ASSOCIATION OF CO-MORBID DISEASE CONDITION IN DIABETIC 
PATIENTS WITH EDS 
 
 
 
 
 
 
 
 
 
S.No Co-morbid Disease  condition Percentage of Patients 
1 Hypertension 36.7 
2 Hypercholestremia 11.3 
3 Foot  Ulcer 27.8 
4 Heart  Disease 3.8 
5 Respiratory Disease 5.1 
6 Acidity 5.1 
7 Blurred Vision 3.8 
8 Kidney Disease 7.6 
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Table: 15 FASTING BLOOD SUGAR LEVEL IN DIABETIC PATIENTS WITH EDS 
S.No FBS Percentage of Patients 
1 Normal (60-100 mg/dl) 5.1 
2 Abnormal (above 100 mg/dl) 94.9 
 
Table: 16 POST PRANDIAL BLOOD SUGAR LEVEL IN DIABETIC PATIENTS 
WITH EDS 
S.No PPBS Percentage of Patients 
1 Normal (120-180 mg/dl) 8.9 
2 Abnormal ( above 180 mg/dl) 91.1 
 
Table: 17 GLYCOSYLATED HAEMOGLOBIN LEVEL IN DIABETIC PATIENTS 
WITH EDS 
S.No HbA1C Percentage of Patients 
1 Normal (5.7-6.9%) 11.4 
2 Abnormal( above 7) 88.6 
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 Table: 18 COMPARISON IN SLEEPING QUALITY USING EPWORTH 
SLEEPINESS SCALE ACCORDING TO GENDER 
 
Variables Male(N=40) Female(N=39) 
Sitting and reading   
Never fall asleep  15(37.5%) 14(35.9%) 
Slight chance of falling asleep        4(10%)) 1(2.6%) 
Medium chance of falling asleep 11(27.5%) 12(30.8%) 
High chance of falling asleep        10(25%) 12(30.8%) 
Watching TV   
Never fall asleep  3(7.5%) 0 
Slight chance of falling asleep 10(25%) 12(30.8%) 
Medium chance of falling asleep     15(37.5%) 13(33.3%) 
High chance of falling asleep 12(30%)    14(35.9%) 
Sitting, inactive in a public place like a 
theatre or meeting 
  
Never fall asleep  3(7.5%) 4(10.3%) 
Slight chance of falling asleep 8(20%) 8(20.5%) 
Medium chance of falling asleep  25(62.5%) 22(56.9%) 
High chance of falling asleep 4(10%) 5(12.8%) 
As a passenger in a car for an hour 
without a break 
  
Never fall asleep  0 0 
Slight chance of falling asleep 6(15%) 2(5.2%) 
Medium chance of falling asleep 4(10%)   7(17.9%) 
High chance of falling asleep 30(75%) 30(76.9%) 
Lying down to rest in the afternoon 
when circumstances permit 
  
Never fall asleep  2(5%) 0 
Slight chance of falling asleep 0 0 
Medium chance of falling asleep 1(2.5%) 1(2.5%) 
High chance of falling asleep 37(92.5%) 38(97.4%) 
Sitting and talking to someone   
Never fall asleep  30(75%) 30(76.9%) 
Slight chance of falling asleep 6(15%)   6(15.4%) 
Medium chance of falling asleep 1(2.5%) 0 
High chance of falling asleep 3(7.5%) 3(7.7%) 
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Variables Male(N=40) Female(N=39) 
Sitting quietly after lunch 
without alcohol 
  
Never fall asleep  3(7.5%) 1(2.6%) 
Slight chance of falling asleep 35(87.5%) 33(84.6%) 
Medium chance of falling asleep 1(2.5%)   4(10.3%) 
High chance of falling asleep 1(2.5%) 1(2.6%) 
In a car, while stopped for a few 
minutes in the traffic 
  
Never fall asleep  33(82.5%) 33(84.6%) 
Slight chance of falling asleep 6(15%) 3(7.7%) 
Medium chance of falling asleep 0              0 
High chance of falling asleep 1(2.5%) 3(7.7%) 
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Table: 19 SLEEPING QUALITY AND ITS PATTERNS IN THE DIABETIC 
POPULATION USING PITTSBURGH SLEEP QUALITY INDEX (PSQI) (N=160) 
 
 
 
Variables 
Patients with 
disturbed 
sleep (N=79) 
Patients 
with good 
Sleep           
(N=81) 
During the past month, how often have you taken 
medicine to help you sleep 
  
Never 72(91.1%) 79(97.5%) 
Once a week 2(2.5%) 1(1.2%) 
More than once a week 5(6.3%) 1(1.2%) 
Wake up in the middle of the night or early 
morning 
  
Never 2(2.5%) 10(12.3%) 
Once a week  38(48.1%) 29(35.8%) 
More than once a week 39(49.4%) 42(51.9%) 
Cannot get to sleep within 30 minutes   
Never 20(25.3%) 49(60.5%) 
Once a week 30(37.9%) 2024.7%) 
More than once a week 29(36.7%) 12(14.8%) 
Have to get up to use the bathroom   
Never 1(1.3%) 2(2.9%) 
Once a week 4(5.1%) 12(14.8%) 
More than once a week 74(93.7%) 67(82.7%) 
Had  bad  Dreams   
Never 28(35.4%) 52(64.2%) 
Once a week 32(40.5%) 28(34.6%) 
More than once a week 19(24.1%) 1(1.2%) 
Have Pain   
Never 24(30.4%) 56(69.1%) 
Once a week 7(8.9%) 13(16%) 
More than once a week 48(60.8%) 12(14.9%) 
 
 
 
 
 
 
  
Results 
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 RESULTS  
 
The prospective study was aimed to find out the probable overall prevalence of 
excessive day time sleepiness in diabetic and obese patients. A total of 160 patients with 
Type II Diabetes Mellitus who were attending diabetic clinic at KMCH, Coimbatore were 
selected as the subjects for the study. 
 
The study population consisted of 88 males and 72 females (Table 1, Fig 1) with an 
average age of 52.06± 8.822 and 50.55 ± 8.838 respectively. 
 
The majority of patients among study population  was within the age group of 56 to 
65 nearly 38.7% followed by 46 to 55 with the percentage of 33.7%  followed by 36 to 45 
with the percentage of 22.5% & 25-35 with a percentage of 5%. (Table 2, figure 2). 
 
The study populations were categorized based on their educational status. It was 
found that 12.5 % of males and 33.3 % of females were illiterates.25% of male and 20.5 % of 
female were having educational qualification up to 10 standard, 37.5 % of male and 23.1% of 
female were having qualification up to 12 standard, remaining 25% of male and 23.1% of 
female were having a qualification of degree or above (Table3, Fig: 3).The study population 
was also categorized based on their monthly income. 46.8% of the population were having a 
monthly income of less than 5000, 36.7% of population were having a monthly income 
between 5000 to 15,000 and the remaining 16.5% of population were having a monthly 
income of more than 15,000.(Table 4,Fig:4) 
 
 The prevalence of Excessive Day time Sleepiness in the study population was found 
by Epworth Sleepiness Scale and Pittsburgh Sleep Quality index. Among the study 
population, 40 males and 39 females were found to have EDS whereas 48 males and 33 
females were found without EDS. (Table 5, Fig: 5).In the study population 45.4% of males 
Results 
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and 54.2% of females were found to have EDS (Table6, Fig:6.1&Fig:6.2). ESS score 
revealed that diabetic females were significantly sleepier than diabetic males during the day 
time.  The majority of patients with EDS were within the age group of 56-65 (36), followed 
by 46-55 (25), followed by 36-45(14), and followed by 25-35 (4). (Table: 7, Fig: 7). The 
association of prevalence of EDS and age group was found out by using chi-square test 
(p≥0.300) indicating that  age group is  not significantly  associated to EDS although older 
age group are more prone to disease. 
 
Body mass index (BMI) was calculated.  Based on the BMI study subjects were 
classified into three groups 18.5 to 24.9, 25 to 29.9 and ≥ 30. According to ESS Scale, 
patients were classified as with EDS and without EDS. In the group of BMI (18-24.9) 31.2% 
of patients were with EDS and 68.8 % of patients were without EDS. In the group of        
BMI( 25-29.9), 62.3% of patients were with EDS and 37.7% of patients were without EDS. 
In the group of BMI ≥ 30 84.2% of patients were with EDS and 15.8% of patients were 
without EDS.  It clearly indicates that BMI is significantly associated with EDS (p=0.000)        
(Table: 8,Fig: 8).Among the subjects with EDS, 37.5% of males and 25.6% of females were 
having BMI in the range of 18-24.9(normal),40% of males and 56.4% of females were 
having BMI in the range of 25-29.9 (overweight) and 22.5% of males and 17.9% of females 
were having a BMI ≥30 (obese).(Table:9,Fig: 9). It clearly indicates that obesity is  higher in 
diabetic females who had high chances of EDS than males. 
 
Based on the physical activity, study subjects were classified into two groups, one 
having moderate and other having sedentary physical activity. In the group having moderate 
physical activity 26 % were with EDS and 74% were without EDS. In the group leading a 
sedentary lifestyle 59.5% were with EDS and 40.5% were without EDS. It clearly indicates a 
strong association of EDS with physical activity (p=0.000)(Table:10,Fig:10). Among the 
Results 
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subjects with EDS, 77.5% of males and 89% of females were leading a sedentary life style 
and 22.5% of males and 10.25% of females were having moderate physical activity.         
(Table 11, Fig:11) It clearly indicates that physical activity is lower in diabetic females with 
poor sleep compared to males.    
 
 Concerned with the duration of diabetes in the study population, 46 patients with 
EDS and 49 patients without EDS had the disease for a period of   0-5 years; 15 patients with 
EDS and 22 patients without EDS had disease for  6-10 years; 13 patients with EDS and 6 
patients without EDS had disease for 11-15 years; 3 patients with EDS and 2 patients without 
EDS had  disease for 16-20 years; and 2 patients with EDS and 1 patient had disease for 21-
25 years of experience.(Table:12,Fig:12) Related to the laboratory data 94.9 % had abnormal 
FBS and 5.1% had normal FBS values, 91.1% had abnormal PPBS and 8.9% had normal 
PPBS values, 88.6% had normal HbA1C and 11.4% had abnormal 
HbA1C.(Table15,16,17,Fig: 15) 
 
 Among the study population ,the subjects were asked about their social habits and it 
was found that 22.2 % of patients with EDS and 15.2% of patients without EDS were 
smokers; 11.1% of patients with EDS and 7.6% of patients without EDS were alcoholics & 
98.2% of patients with EDS and 95% of patients without EDS have a habit of taking either 
tea /coffee.(Table 13,Fig:13) Shift workers are more prone to EDS. Out of 5 shift workers 
who visited Diabetic clinic during the study period ,4 were having EDS. 
 
Risk factors like hypertension (36.7%), Foot Ulcer (27.8), Hypercholestremia (11.3%) 
and heart disease (3.8%) were more frequent in diabetic patients with EDS.(Table 14,Fig:14) 
 
Table 19 shows the sleeping quality, excessive daytime sleepiness and its patterns in 
the diabetic population using the Pittsburgh sleep quality index (PSQI).72(91%) of the 
Results 
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patients with disturbed sleep and 79(97.5%) of the patients with good sleep have never taken 
any medicine to help them sleep. 2(2.5%) of the patients with disturbed sleep and 1 
(1.2%) of the patients with good sleep have taken medicine once a week to help them sleep.     
5(6.3% ) of the patients with disturbed sleep 1(1.2%)of the  patient with good sleep  have 
taken medicine more than once in  a week to help them sleep.2(2.5%) of the patients with 
disturbed sleep and 10 (12.3%)  of the patients with good sleep have  never waken up in the 
middle of the night or early morning.38(48.1%) of the patients with disturbed sleep and      
29( 35.8%) of the patients with good sleep  have waken up  once a week in the middle of the 
night or early morning.39(49.41%)of the patients with disturbed sleep and 42(51.9%) of the 
patients with good sleep have waken up more than once in a week.20(25.3%) of the patients  
with disturbed sleep and 49(60.5%) of the patients  with good sleep have never taken more 
than 30 minutes to get sleep.30(37.9%) of the patients with disturbed sleep and 20(24.7%) of  
the patients with good sleep have taken more than 30 minutes to get sleep once a 
week.29(36.7%) of the patients with disturbed sleep and 12(14.8%) of the patients with good 
sleep have taken more  than 30 minutes  to get sleep more than once in a week.1(1.3%) 
patients with disturbed sleep and 2(2.9%) patients with good sleep have never got up to use 
the bathroom.4(5.1%) patients with disturbed sleep and 12(14.8%) patients with disturbed 
sleep have got up once a week to use the bathroom.74(93.7%) patients with disturbed sleep 
and 67(82.7%) patients with good sleep have got up more than once in a week.28(35.4%) 
with disturbed sleep and 52(64.2%) with good sleep never had bad dreams.32(40.5%) 
patients with disturbed sleep  and 28(34.6%) of patients with good sleep had bad dreams once 
a week.19(24.1%) patients with disturbed sleep and 1(1.2%) patient with good sleep had bad 
dreams more than once  in a week. 24(30.4%) of patients with disturbed sleep and 56(69%) 
patients with good sleep  never had pain.7(8.9%) patients with disturbed sleep and 13(16%) 
Results 
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patients with good sleep had pain once a week.48(60.8%) patients with disturbed sleep and 
12(14.9%) patients with good sleep had  pain more than once in  a week. 
 
Table18 shows the comparison in sleeping quality in studied subjects using Epworth 
sleepiness scale (ESS). Female diabetic patients had high chances of falling asleep during the 
day time than males; sitting and reading (30.8% vs 25%), watching TV (35.9% vs 30%) 
sitting inactive in a public place (12.8% vs 10%), as a passenger in a car (76.9%% vs 75%), 
lying down to rest in the afternoon (97.4% vs 92.5%), sitting and talking to someone (7.7% 
vs 7.5%),sitting quietly after lunch without alcohol(2.6% vs 2.5%) and in a car while stopped 
for few minutes in traffic (7.7% vs 2.5%). ESS score results showed that diabetic women 
were sleepier (54.2 %) than men (45.4 %) during the day-time. 
Discussion 
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DISCUSSION 
 
 
Diabetes mellitus is a major public health problem, causing significant morbidity and 
mortality. Across different populations, several studies have found sleep disturbances in patients 
with diabetes mellitus in relation with their quality of life. However, the relationship between 
sleep disorders and diabetes mellitus is less understood and less studied.The current study is a 
study using the Epworth sleepiness scale (ESS) and Pittsburgh sleep quality index (PSQI) to 
examine the sleep quality and excessive day-time sleepiness (EDS) in the diabetic population. 
Recent literature suggests that it may also be associated with the metabolic syndrome, for 
example: obesity, diabetes, insulin resistance. Even in the present study, the data revealed that 
there is a strong association between EDS and diabetes. This finding suggests that diabetes 
should be considered whenever a complaint of EDS is present in individuals.71-73 
  
A study conducted by Abdulbari Bener et al has demonstrated a high proportion of 
sleep loss (60.1%) in Arab diabetic population residing in the State of Qatar. Among the studied 
diabetic patients, female diabetic patients (57%) were likely to have more sleep loss than male 
(43%) in the Arab population in Qatar.
36
 It was also reported in a study by Suarez that Sleep 
quality and symptoms of poor sleep have been linked to increased risk of type 2 DM with recent 
evidence suggesting stronger associations in women.
74 
 
In the present study, diabetic patients (49.4%) reported high chances of daytime 
sleepiness. Among the studied diabetic patients, female diabetic patients (54.2 %) were likely to 
have excessive daytime sleepiness than males (45.4%). Another study done in Japan among male 
population, Kawa-kami et al reported a high incidence of diabetes in male subjects reporting 
sleeping disturbances after controlling other factors relevant to type 2 DM. These studies identify 
Discussion 
 
Prevalence and Assessment of Excessive Daytime Sleepiness in Diabetic and Obese Patients   
 
45 
sleep as a potential factor influencing glucose control in a specific population of patients with 
type 2 DM.
75  
 
In this study, quality of sleep varied by gender in diabetic patients. There was a 
considerable difference observed in ESS scores between both sexes. This is in contrast with 
another study by Walker RD et al that no significant difference was observed in ESS scores 
between both genders
76
.  
 
Female diabetic patients had high chances of falling asleep during the daytime than men 
especially while sitting and reading. (30.8% vs 25%), watching TV (35.9% vs 30%) sitting 
inactive in a public place (12.8% vs 10%), as a passenger in a car (76.9%% vs 75%), lying down 
to rest in the afternoon (97.4% vs 92.5%), sitting and talking to someone (7.7% vs 7.5%),sitting 
quietly after lunch without alcohol(2.6% vs 2.5%) and in a car while stopped for few minutes in 
traffic (7.7% vs 2.5%). Another study by Meisinger et al demonstrated that the men and women 
who reported a high frequency of sleep loss had a significantly higher risk for type 2 DM.
77 
 
 Thus, poor diabetes control could contribute both to a higher perceived sleep debt and 
lower sleep quality. Sleep disturbances with DM could be caused by either physical or 
psychological discomfort due to the disorder. This shows that quality of life is vital for health 
and well being in persons with type 2 DM. 
 
E.O Bixler et al in their study observed a strong association between EDS and BMI. 
Until the overweight threshold was reached, the BMI specific prevalence of EDS remained 
constant. Beyond this BMI threshold, the prevalence of EDS increased in an exponential 
manner.
40
 This is in accordance with the present study. In the group of BMI (18-24.9) 31.2% of 
patients were with EDS and 68.8 % of patients were without EDS. In the group of BMI( 25-
Discussion 
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29.9), 62.3% of the patients were with EDS and 37.7% of the patients were without EDS. In the 
group of BMI ≥ 30 84.2% of the patients were with EDS and 15.8% of the patients were without 
EDS. Abdulbari Bener et al in their study found that obesity was significantly higher in diabetic 
females with higher chances of falling asleep during day time (51.7%)than in males(39.3%).
36
  In 
the present study, among the subjects with EDS 40% of males and 56.4% of females were having 
BMI in the range of 25-29.9 (overweight) and 22.5% of males and 17.9% of females were 
having a BMI ≥30 (obese).Physical activity was significantly less in diabetic females(38.6%) 
compared to men (50.2%).
36
This result is  also in accordance with the present study. In the group 
leading a sedentary lifestyle 59.5% were with EDS and 40.5% were without EDS. It clearly 
indicates a strong association of EDS with physical activity. Among the subjects with EDS, 
77.5% of males and 89% of females were leading a sedentary life style.  
 
Sleep efficiency declines with increasing age. With increasing age the homeostatic sleep 
mechanism weakens affecting both night time sleep efficiency and day time sleep propensity
40
 
.The majority of patients with EDS were within the age group of 56-65 (36), followed by 46-55 
(25), followed by 36-45(14), and followed by 25-35 (4). 
 
Foley D et al., in their study reported that that males and females with sleep disturbance 
were more likely to be obese to have a history of hypertension.
13 
36.7% of patients with EDS had 
hypertension. Hence the alarming rise in sleep loss among female population is due to rising 
problem of obesity and chronic diseases.  
Conclusion 
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CONCLUSION 
 
The study findings observed that excessive day time sleepiness is more prevalent in 
diabetic obese population. Sleep loss varies considerably by gender in diabetic patients. It was 
more observed in diabetic females than males. Obesity was also more common in diabetic 
women than in men while physical activity was less in women compared to men. A sedentary 
lifestyle has shown to enhance excessive day time sleepiness in diabetic patients. Difference was 
observed in the ESS scores between both genders. Sleep disturbances were seen more common 
in older age group of 55-65. Most of the patients observed with EDS had hypertension as a co-
morbid disease. 
 
Sleep exerts marked modulatory effects on glucose metabolism by influencing the 
balance and levels of hormones, including leptin, ghrelin, insulin and cortisol, in addition to the 
activity of the sympathetic nervous system(SNS). These physiological defence mechanisms alter 
glucose tolerance and sensitivity to insulin and leptin, impairing appetite regulation. Therefore, 
when chronically activated, these stress responses favour the development of obesity and T2DM. 
In addition, shorter sleepers have more opportunity for food consumption and tend to be more 
fatigued and less active during the day, which favour obesity. On the other hand, obesity itself, 
especially when central, leads to OSA, to inflammatory processes, and to the development of 
T2DM. Thus, we may conclude that it is difficult to isolate a cause and an effect from this neuro-
endocrine-metabolic misbalance, since sleep characteristics (disorders or duration) may   impact 
neurological and endocrine systems to promote obesity and T2DM, while obesity and T2DM 
may impact sleep as well. Therefore, while obesity and T2DM are favoured 
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and aggravated by short sleep duration or sleep disorders, sleep may be impaired by these two 
widespread metabolic conditions.  
 
  Thus sleep quality is seen poor in diabetic patients. To improve sleep quality, a clinical 
pharmacist can help patients to follow good sleep habits. The pharmacist encourages patients to 
engage in good sleep hygiene to reduce daytime sleepiness and instruct patients that adequate 
high-quality sleep is important to improve daytime function. Good sleep hygiene includes 
ensuring adequate sleep duration, developing sleep promoting bedtime rituals, avoiding staying 
in bed if unable to sleep, and avoiding caffeine if it disturbs the patient’s ability to fall asleep. 
There are many effective treatments for sleep disorders, and the deleterious health effects of 
insufficient sleep or a coexisting sleep disorder warrant greater attention. Pharmacist can be 
instrumental in encouraging adherence to treatment for sleep disorders. Although persons with 
diabetes are instructed to restrict calories and to increase physical activity, the presence of less 
than optimal sleep may undermine these important treatment goals. Thus, educating patients with 
type 2 diabetes about the importance of sleep and regular screening for sleep disorders has the 
potential for a positive clinical outcome. 
  
 Thus the need of setting up of  Sleep Disorder clinics at diabetological centres have 
become quiet an essential part, as the number of diabetic obese population is increasing at an 
alarming rate day by day. This enables the diabetic population to improve their quality of life. 
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Annexures 
 
Epworth Sleepiness Scale
Name:
Date:
Your age: (Yr) Your sex:        Male       Female 
How likely are you to doze off or fall asleep in the situations described below,
in contrast to feeling just tired?
This refers to your usual way of life in recent times.
Even if you haven't done some of these things recently try to work out 
how they would have affected you.
Use the following scale to choose the most appropriate number for each situation:-
0  =  would never doze
1  = Slight chance of dozing
2  = Moderate chance of dozing
3  = High chance of dozing
Situation Chance of dozing
Sitting and reading  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Watching TV  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sitting, inactive in a public place (e.g. a theatre or a meeting)  . . . . . . .
As a passenger in a car for an hour without a break  . . . . . . . . . . . . . . .
Lying down to rest in the afternoon when circumstances permit  . . . . .
Sitting and talking to someone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sitting quietly after a lunch without alcohol  . . . . . . . . . . . . . . . . . . . . . .
In a car, while stopped for a few minutes in the traffic  . . . . . . . . . . . . .
Total  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
Score:
0-10 Normal range
10-12 Borderline
12-24 Abnormal
 
 
   
Pittsburgh Sleep Quality Index (PSQI) 
 
 
      Instructions: The following questions relate to your usual sleep habits during the past month only. Your answers  
      should indicate the most accurate reply for the majority of days and nights in the past month. Please answer          
      all questions.   
 
      1. During the past month, what time have you usually gone to bed at night? ___________________  
2. During the past month, how long (in minutes) has it usually taken you to fall asleep each night? __________ 
3. During the past month, what time have you usually gotten up in the morning?  ___________________  
4. During the past month, how many hours of actual sleep did you get at night? (This may be different than the 
number of hours you spent in bed.) ___________________  
 
5. During the past month, how often have you had  Not during  Less than  Once or  Three or more 
trouble sleeping because you…  the past  once a  twice a   times a week 
 month  week week   
a.  Cannot get to sleep within 30 minutes      
b.  Wake up in the middle of the night or early 
     morning    
    
c.  Have to get up to use the bathroom      
d.  Cannot breathe comfortably      
e.  Cough or snore loudly      
f.   Feel too cold      
g.  Feel too hot      
h.  Have bad dreams      
i.   Have pain      
j.   Other reason(s), please describe:     
     
     
6. During the past month, how often have you 
taken medicine to help you sleep (prescribed or 
“over the counter”)?   
    
7. During the past month, how often have you had      
trouble staying awake while driving, eating meals, 
or engaging in social activity? 
    
 No Only a Somewhat A very big 
 problem very slight of a problem 
 at all problem problem  
8. During the past month, how much of a problem 
has it been for you to keep up enough enthusiasm 
to get things done?                 
    
 Very  Fairly  Fairly  Very 
 good good bad bad 
9.  During the past month, how would you rate 
your sleep quality overall? 
    
     
 
 
Name:__________________________________________                         Date: ________________ 
   
 No bed 
partner or 
room mate 
Partner/room 
mate in 
other room 
Partner in 
same room but 
not same bed 
Partner in 
same bed 
10.  Do you have a bed partner or room   
mate? 
    
 
Not during 
the past 
month 
Less than 
once a week 
Once or twice 
a week 
Three or 
more times 
a week 
If you have a room mate or bed partner, ask 
him/her how often in the past month you have 
had: 
    
a.  Loud snoring     
b.  Long pauses between breaths while asleep     
c.  Legs twitching or jerking while you sleep       
d.  Episodes of disorientation or confusion  
     during sleep 
    
e.  Other restlessness while you sleep, please 
     describe: 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Scoring the PSQI 
 
The order of the PSQI items has been modified from the original order in order to 
fit the first 9 items (which are the only items that contribute to the total score) on a single 
page. Item 10, which is the second page of the scale, does not contribute to the PSQI 
score.  
 
 In scoring the PSQI, seven component scores are derived, each scored 0 (no 
difficulty) to 3 (severe difficulty). The component scores are summed to produce a global 
score (range 0 to 21). Higher scores indicate worse sleep quality. 
 
Component 1: Subjective sleep quality—question 9 
Response to Q9  Component 1 score 
Very good    0 
Fairly good   1 
Fairly bad    2 
Very bad    3 
        Component 1 score:_____ 
Component 2: Sleep latency—questions 2 and 5a 
Response to Q2  Component 2/Q2 subscore 
< 15 minutes   0 
16-30 minutes   1 
31-60 minutes   2 
> 60 minutes   3 
 
Response to Q5a  Component 2/Q5a subscore 
Not during past month  0 
Less than once a week  1 
Once or twice a week  2 
Three or more times a week 3 
 
Sum of Q2 and Q5a subscores Component 2 score  
0     0 
1-2     1 
3-4     2 
5-6     3 
        Component 2 score:_____ 
Component 3: Sleep duration—question 4 
Response to Q4  Component 3 score 
> 7 hours    0 
6-7 hours    1 
5-6 hours    2 
< 5 hours    3 
        Component 3 score:_____ 
Component 4: Sleep efficiency—questions 1, 3, and 4 
 Sleep efficiency = (# hours slept/# hours in bed) X 100% 
   # hours slept—question 4 
   # hours in bed—calculated from responses to questions 1 and 3 
Sleep efficiency  Component 4 score 
> 85%    0 
75-84%    1 
65-74%    2 
< 65%    3 
        Component 4 score:_____ 
 
   
Component 5: Sleep disturbance—questions 5b-5j 
Questions 5b to 5j should be scored as follows: 
Not during past month  0 
Less than once a week  1 
Once or twice a week  2 
Three or more times a week 3 
 
Sum of 5b to 5j scores  Component 5 score 
0 0 
1-9 1 
10-18    2 
19-27    3 
        Component 5 score:_____ 
Component 6: Use of sleep medication—question 6 
Response to Q6   Component 6 score 
Not during past month  0 
Less than once a week  1 
Once or twice a week  2 
Three or more times a week 3 
        Component 6 score:_____ 
Component 7: Daytime dysfunction—questions 7 and 8 
Response to Q7  Component 7/Q7 subscore 
Not during past month  0 
Less than once a week  1 
Once or twice a week  2 
Three or more times a week 3 
 
Response to Q8  Component 7/Q8 subscore 
No problem at all   0 
Only a very slight problem 1 
Somewhat of a problem   2 
A very big problem  3 
 
Sum of Q7 and Q8 subscores Component 7 score  
0     0 
1-2     1 
3-4     2 
5-6     3 
        Component 7 score:_____ 
 
Global PSQI Score: Sum of seven component scores:___________ 
 
 
Copyright notice:  The Pittsburgh Sleep Quality Index (PSQI) is copyrighted by Daniel J. 
             Buysse, M.D.  Permission has been granted to reproduce the scale on this 
     website for clinicians to use in their practice and for researchers to use in non- 
      industry studies.  For other uses of the scale, the owner of the copyright should  
       be contacted.   
 
 
Citation: Buysse, DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh 
Sleep Quality Index (PSQI): A new instrument for psychiatric research and 
practice. Psychiatry Research 28:193-213, 1989 
 
 
 
 
  
                                      
                                  
                                       
 DATA ENTRY FORM  
                                                                                   
 
 
 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
OP / IP No: .………………………                         Age: …........Years          Sex: Male / Female 
 
                                                                                  Nationality:        
                                                                                    
Name:                                                                      Monthly Income: Rs: ……………………… 
 
Address:                                                                  Education level :        ……………………….        
                                                                                  
                                                                                 Occupation :               ………………………. 
                                                                                 
                                                                                  
Ph no: 
 
 
Ph No: 
 
Duration of Diabetes  : …………     Marital Status  : …………… Physical activity:………… 
 
   
Height : ……….     Weight : ………    BMI :  ………….   Waist circumference :  ……….. 
 
Smoking:………    Alcohol:………..    Tea/ Coffee: ………..  Shift work: …………… 
            
   
 
                                            
                   
 
           
 
   
 
 
RBS     : …………………mg/dL                       Total cholesterol    : ………………. mg/dl 
FBS     : …………………mg/dL                        HDL                       : ……………...... mg/dl 
 
PPBS   : …………............mg/dL                       VLDL                     : ….…………….. mg/dl 
 HbA1c : …………………%                              LDL                        : ...………………mg/dl 
 
Blood  Pressure : …………mm Hg                   Triglycerides        : ………………....mg/dl 
 
Urine Analysis : 
 
                                                                          
 
                                                                                                                                                                                                                                
WHY DO WE NEED SLEEP? 
 
 Rest and recharge our bodies 
  Aid memory and learning 
 Ensure normal hormone 
secretion 
  Maintain normal immune 
function 
 Heal and repair body tissues 
 Maintain optimal emotional and social functioning while awake 
 
TIPS ON GETTING TO SLEEP 
 Aim for at least 6 to 8hours of 
uninterrupted sleep every night. 
  Try to go to bed at the same time 
and get up at the same time every 
day - routine will encourage good 
quality sleep. 
 
  Avoid naps during the day to ensure that you are tired at bedtime. 
 Try to go to bed only when you are sleepy - this will reduce the amount of time 
you are awake in bed. 
TIPS ON GETTING TO SLEEP cont… 
 Try not to become stressed if you feel you are not getting enough sleep. 
Remember that sleep will come eventually, and try to relax. 
 Avoid looking at the clock while in bed. If you can’t get to sleep or get back to 
sleep for an extended period, get out of bed and do something boring in very 
dim light, or sit and relax in the dark until you are sleepy. 
 Exercising in the morning or early afternoon can encourage a healthy sleep 
routine. Exercise 3 to 5times a week is recommended. 
  Keep your bedroom at a cool, comfortable temperature, and maintain a dark 
and quiet sleeping environment. 
 It’s best not to watch television 
in bed, because this may 
stimulate your brain and delay 
sleep onset. 
 Do not go to bed hungry 
similarly  don’t eat a heavy meal 
before bed. Both can interfere 
with sleep. 
 Avoid consuming alcohol at least 4 hours before going to bed. It can seem to 
help you fall asleep, but it also causes disrupted sleep. 
 Caffeine and tobacco are both stimulants; Avoid caffeine and smoking at least 
4 hours before going to bed. 
